Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73–8.
Article
CAS
Google Scholar
Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, Vanderheiden A, Nyhoff L, Davis CW, Adekunle O. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3): 100040.
Article
CAS
Google Scholar
Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, Heine PA, Ballmann R, Schneider K-T, Roth KDR. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12(1):1–15.
Article
Google Scholar
Akama-Garren EH, Li JX. Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: a retrospective study of 835 patients. J Med Virol. 2021. https://doi.org/10.1002/jmv.27105.
Article
PubMed
PubMed Central
Google Scholar
Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291–3.
Article
Google Scholar
Day AL, Winthrop KL, Curtis JR. The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleve Clin J Med. 2020;87(11):695–703.
Article
Google Scholar
Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, El-Qunni AA, Haile A, Huang K, Kinnett B: Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Annals of internal medicine 2021.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.
CAS
PubMed
PubMed Central
Google Scholar
Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines. 2014;13(2):285–98.
Article
CAS
Google Scholar
Huzly D, Panning M, Smely F, Enders M, Komp J, Falcone V, Steinmann D. Accuracy and real life performance of a novel interferon-γ release assay for the detection of SARS-CoV2 specific T cell response. J Clin Virol. 2022;148: 105098.
Article
CAS
Google Scholar
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.
Article
Google Scholar
Pearce FA, Lanyon PC, Grainge MJ, Shaunak R, Mahr A, Hubbard RB, Watts RA. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford). 2016;55(9):1656–63.
Article
Google Scholar
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525–9.
Article
CAS
Google Scholar
Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021. https://doi.org/10.1136/annrheumdis-2021-220604.
Article
PubMed
Google Scholar
Jinich S, Schultz K, Jannat-Khah D, Spiera R. B-cell reconstitution is strongly associated with COVID-19 vaccine responsiveness in rheumatic disease patients treated with rituximab. Arthritis Rheumatol. 2021. https://doi.org/10.1002/art.42034.
Article
Google Scholar
Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, Möller B, Njue LM, Medri C, Angelillo-Scherrer A, Borradori L. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–97.
Article
Google Scholar
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345–50.
Article
CAS
Google Scholar
Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A. B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheumatol. 2021. https://doi.org/10.1002/art.42060.
Article
Google Scholar
Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2021;4(3):e177–87.
Article
Google Scholar
Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Bitu M, Ly B. Rituximab Impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol. 2022;74(6):927–33.
Article
CAS
Google Scholar
Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I, Mangsbo S, Burman J. Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated With Rituximab. JAMA Netw Open. 2022;5(5):e2211497–e2211497.
Article
Google Scholar
Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Provstgaard-Morys S, Clutterbuck E, Ramasamy MN, Aley PK, Farooq Mujadidi Y: Safety and immunogenicity report from the com-COV study–a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. 2021.
https://doi.org/10.1016/S0140-6736(21)01694-9
Borobia AM, Carcas AJ, Pérez Olmeda MT, Castaño L, Jesús Bertrán M, García-Pérez J, Campins M, Portolés A, Gonzalez-Perez M, García Morales MT. Reactogenicity and immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, phase 2 trial (CombiVacS). Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)01420-3.
Article
PubMed
PubMed Central
Google Scholar
Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255–65.
Article
CAS
Google Scholar
Kolb T, Fischer S, Müller L, Lübke N, Hillebrandt J, Andrée M, Schmitz M, Schmidt C, Kücükköylü S, Koster L. Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients. Kidney360. 2021. https://doi.org/10.34067/KID.0003512021.
Article
PubMed
PubMed Central
Google Scholar
Sanders JSF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frölke SC, Geers D, GeurtsvanKessel CH. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821–34.
Article
CAS
Google Scholar
Jena A, Mishra S, Deepak P, Kumar MP, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2021. https://doi.org/10.1016/j.autrev.2021.102927.
Article
PubMed
PubMed Central
Google Scholar